An antisense oligonucleotide targeting the αV integrin gene inhibits adhesion and induces apoptosis in breast cancer cells

European Journal of Cancer

Volumn 36, Issue 3, 2000, Pages 397-409

  Townsend, P A ^a   Villanova, I ^b   Uhlmann, E ^c   Peyman, A ^c   Knolle, J ^c   Baron, R ^c,d   Teti, A ^b   Horton, M A ^e  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c SANOFI   (France)

^d YALE UNIVERSITY   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

V integrin; Bone metastasis; Breast cancer; Osteoclasts; Osteolytic lesions

Indexed keywords

ACTIN; ANTISENSE OLIGONUCLEOTIDE; FIBRONECTIN; INTEGRIN; LAMININ; MESSENGER RNA; PROTEIN P53; VITRONECTIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL ADHESION; CELL CULTURE; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTIGENS, CD; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; DENSITOMETRY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HUMANS; INTEGRIN ALPHAV; MICROSCOPY, FLUORESCENCE; OLIGONUCLEOTIDES, ANTISENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034000614     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00275-0     Document Type: Article

References (42)

1. Mundy GR. Malignancy and the skeleton. Horm Metab Res 1997, 29, 120-127.
2. Harvey HA. Issues concerning the role of chemotherapy and hormonal therapy on bone metastasis from breast carcinoma. Cancer 1997, 80, 1646-1651.
3. Clezardin P. Recent insights into the role of integrins in cancer metastasis. Cell Mol Life Sci 1998, 54, 541-548.
4. Hynes RO. Integrins: a family of cell surface receptors. Cell 1987, 48, 549-554.
5. Green LJ, Mould AP, Humpries MJ. The integrin beta subunit. Int J Biochem Cell Biol 1998, 30, 179-184.
6. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992, 69, 11-25.
7. Meredith JE Jr, Winitz S, McArthur Lewis J, et al. The regulation of growth and intracellular signaling by integrins. Endocrine Rev 1996, 17, 207-220.
8. Meyer T, Marshall JF, Hart IR. Expression of αV integrins and vitronectin receptor identity in breast cancer cells. Br J Cancer 1998, 77, 530-536.
9. Marshall JF, Hart IR. The role of αV-integrins in tumour progression and metastasis. Cancer Biol 1996, 7, 129-138.
10. Marshall JF, Nesbitt SA, Helfrich MH, Horton MA, Polakova K, Hart IR. Integrin expression in human melanoma cell lines: heterogeneity of vitronectin receptor composition and function. Int J Cancer 1991, 49, 924-931.
11. Gehlsen KR, Davis GE, Sriramarao P. Integrin expression in human melanoma cells with differing invasive and metastatic properties. Clin Exp Metastasis 1992, 10, 111-120.
12. Stein CA, Narayanana R. Antisense oliodeoxynucleotides. Curr Opin Oncol 1994, 6, 587-594.
13. Rojanasakul Y. Antisense oligonucleotide therapeutics: drug delivery and targeting. Adv Drug Delivery Rev 1996, 18, 115-131.
14. Egli M. Conformational preorganization, hydration, and nucleic acid duplex stability. Antisense Nucleic Acid Drug Dev 1998, 8, 123-128.
15. Uhlmann E, Peyman A. Antisense oligonucleotides - a new therapeutic principle. Chem Rev 1990, 90, 543-584.
16. Horton MA, Lewis D, McNutly K, Pringle JAS, Fuller K, Chambers TJ. Monoclonal antibodies to osteoclastomas (giant cell tumours): definition of osteoclast-specific antigens. Cancer Res 1985, 45, 5663-5669.
17. Freed E, Gailit J, van der Geer P, Ruoslahti E, Hunter T. A novel integrin β subunit is associated with the vitronectin receptor α subunit (αV) in a human osteosarcoma cell line and is a substrate for protein kinase C. EMBO J 1989, 8, 2955-2965.
18. Fitzgerald LA, Poncz M, Steiner R, Rall Jr SC, Bennett JS, Phillips DR. Comparison of cDNA-derived protein sequences of the human fibronectin and vitronectin receptor alpha-subunits and platelet glycoprotein lib. Biochemistry 1987, 26, 8158-8165.
19. Nip J, Rabbani SA, Shibata HR, Brodt P. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J Clin Invest 1995, 95, 2095-2103.
20. Peyman A, Uhlmann E. Minimally modified oligonucleotides-combination of end-capping and pyrimidine protection. Biol Chem 1996, 37, 67-70.
21. 3H-1,2-Benzodithiole-3-onel,1-dioxide as an improved sulfurizing reagent in the solid-phase synthesis of oligodeoxynucleoside phosphorothioates. J Am Chem Soc 1990, 112, 1253-1254.
22. Fattman CL, An B, Sussman L, Dou QP. p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifene-induced apoptosis in human breast carcinoma cells. Cancer Lett 1998, 130, 103-113.
23. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339, 357-363.
24. Clohisy DR, Palkert D, Rammaraine ML, Pekurovsky I, Oursler MJ. Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis. J Orthop Res 1996, 14, 396-402.
25. Yoneda T. Mechanisms of preferential metastasis of breast cancer to bone. Int J Oncol 199, 9, 103-109.
26. Sung V, Stubbs JT 3rd, Fisher L, Aaron AD, Thompson EW. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J Cell Physiol 1998, 176, 482-494.
27. Liapis H, Flath A, Kitazawa S. Integrin alpha V beta 3 expression by bone-residing breast cancer metastasis. Diagn Mol Pathol 1996, 5, 127-135.
28. Horton MA. The aVb3 integrin "vitronectin receptor". Int J Biochem Cell Biol 1997, 29, 721-725.
29. Duong LT, Rodan GA. Integrin-mediated signaling in the regulation of osteoclast adhesion and activation. Front Biosci 1998, 3, D757.
30. Wong NC, Mueller BM, Barbas CF, et al. Alpha V integrins mediate adhesion and migration of breast carcinoma. Clin Exp Metastasis 1998, 16, 50-61.
31. Stein CA. Controversies in the cellular pharmacology of oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev 1997, 7, 201-209.
32. Brooks PC, Montgomery AMP, Rosenfield M, et al. Integrin αVβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79, 1157-1164.
33. Brooks PC, Strömblad S, Klemenke R, Vissecher D, Sarkar FH, Cheresh DA. Antiintegrin αVβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995, 96, 1815-1822.
34. WAF1/CIP1 expression by vascular cell integrin αVβ3 during angiogenesis. J Clin Invest 1996, 98, 426-433.
35. Villanova I, Townsend PA, Uhlmann E, et al. Oligodeoxynucleotide targeted to the (V gene inhibits integrin synthesis, impairs osteoclast function and activates intracellular signals to apoptosis. J Bone Min Res 1999, 14, 1867-1879.
36. Hale AJ, Smith CA, Sutherland LC, et al. Apoptosis: molecular regulation of cell death. Eur J Biochem 1996, 23, 1-26.
37. Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell 1998, 1, 553-563.
38. White E. Life, death, and the pursuit of cell death. Genes Develop 1996, 10, 1-15.
39. Fox SB, Leek RD, Bliss J, et al. Association of tumor angiogenesis with bone marrow micrometastasis in breast cancer patients. J Natl Cancer Inst 1997, 89, 1044-1049.
40. Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997, 99, 2509-2517.
41. Sasaki A, Kitamura K, Alcalde RE, et al. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int J Cancer 1998, 77, 279-285.
42. Carron CP, Meyer DM, Pegg JA, et al. A peptidomimetic antagonist of the integrin αVβ3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res 1998, 58, 1930-1935.